Advanced search
1 file | 562.62 KB Add to list

Handling of allergen immunotherapy in the COVID-19 pandemic : an ARIA-EAACI statement

(2020) ALLERGY. 75(7). p.1546-1554
Author
Organization
Abstract
The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
Keywords
allergy treatment, clinical immunotherapy, immunotherapy vaccines and mechanisms, VENOM ALLERGY, ASTHMA, MECHANISMS, VACCINES

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 562.62 KB

Citation

Please use this url to cite or link to this publication:

MLA
Klimek, Ludger, et al. “Handling of Allergen Immunotherapy in the COVID-19 Pandemic : An ARIA-EAACI Statement.” ALLERGY, vol. 75, no. 7, 2020, pp. 1546–54, doi:10.1111/all.14336.
APA
Klimek, L., Jutel, M., Akdis, C., Bousquet, J., Akdis, M., Bachert, C., … Zuberbier, T. (2020). Handling of allergen immunotherapy in the COVID-19 pandemic : an ARIA-EAACI statement. ALLERGY, 75(7), 1546–1554. https://doi.org/10.1111/all.14336
Chicago author-date
Klimek, Ludger, Marek Jutel, Cezmi Akdis, Jean Bousquet, Mubeccel Akdis, Claus Bachert, Ioana Agache, et al. 2020. “Handling of Allergen Immunotherapy in the COVID-19 Pandemic : An ARIA-EAACI Statement.” ALLERGY 75 (7): 1546–54. https://doi.org/10.1111/all.14336.
Chicago author-date (all authors)
Klimek, Ludger, Marek Jutel, Cezmi Akdis, Jean Bousquet, Mubeccel Akdis, Claus Bachert, Ioana Agache, Ignacio Ansotegui, Anna Bedbrook, Sinthia Bosnic-Anticevich, G. Walter Canonica, Tomas Chivato, Alvaro A. Cruz, Wienia Czarlewski, Stefano Del Giacco, Hui Du, Joao A. Fonseca, Yadong Gao, Tari Haahtela, Karin Hoffmann-Sommergruber, Juan-Carlos Ivancevich, Nikolai Khaltaev, Edward F. Knol, Piotr Kuna, Desiree Larenas-Linnemann, Erik Melen, Joaquim Mullol, Robert Naclerio, Ken Ohta, Yoshitaka Okamoto, Liam O’Mahony, Gabrielle L. Onorato, Nikos G. Papadopoulos, Ruby Pawankar, Oliver Pfaar, Boleslaw Samolinski, Jurgen Schwarze, Sanna Toppila-Salmi, Mohamed H. Shamji, Maria Teresa Ventura, Arunas Valiulis, Arzu Yorgancioglu, Paolo Matricardi, and Torsten Zuberbier. 2020. “Handling of Allergen Immunotherapy in the COVID-19 Pandemic : An ARIA-EAACI Statement.” ALLERGY 75 (7): 1546–1554. doi:10.1111/all.14336.
Vancouver
1.
Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, et al. Handling of allergen immunotherapy in the COVID-19 pandemic : an ARIA-EAACI statement. ALLERGY. 2020;75(7):1546–54.
IEEE
[1]
L. Klimek et al., “Handling of allergen immunotherapy in the COVID-19 pandemic : an ARIA-EAACI statement,” ALLERGY, vol. 75, no. 7, pp. 1546–1554, 2020.
@article{8693862,
  abstract     = {{The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.}},
  author       = {{Klimek, Ludger and Jutel, Marek and Akdis, Cezmi and Bousquet, Jean and Akdis, Mubeccel and Bachert, Claus and Agache, Ioana and Ansotegui, Ignacio and Bedbrook, Anna and Bosnic-Anticevich, Sinthia and Canonica, G. Walter and Chivato, Tomas and Cruz, Alvaro A. and Czarlewski, Wienia and Del Giacco, Stefano and Du, Hui and Fonseca, Joao A. and Gao, Yadong and Haahtela, Tari and Hoffmann-Sommergruber, Karin and Ivancevich, Juan-Carlos and Khaltaev, Nikolai and Knol, Edward F. and Kuna, Piotr and Larenas-Linnemann, Desiree and Melen, Erik and Mullol, Joaquim and Naclerio, Robert and Ohta, Ken and Okamoto, Yoshitaka and O'Mahony, Liam and Onorato, Gabrielle L. and Papadopoulos, Nikos G. and Pawankar, Ruby and Pfaar, Oliver and Samolinski, Boleslaw and Schwarze, Jurgen and Toppila-Salmi, Sanna and Shamji, Mohamed H. and Ventura, Maria Teresa and Valiulis, Arunas and Yorgancioglu, Arzu and Matricardi, Paolo and Zuberbier, Torsten}},
  issn         = {{0105-4538}},
  journal      = {{ALLERGY}},
  keywords     = {{allergy treatment,clinical immunotherapy,immunotherapy vaccines and mechanisms,VENOM ALLERGY,ASTHMA,MECHANISMS,VACCINES}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{1546--1554}},
  title        = {{Handling of allergen immunotherapy in the COVID-19 pandemic : an ARIA-EAACI statement}},
  url          = {{http://dx.doi.org/10.1111/all.14336}},
  volume       = {{75}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: